In-depth research profiles for every compound. Dosing protocols, reconstitution math, mechanisms of action, side effects, and peer-reviewed references.
GLP-1 receptor agonist. FDA-approved for weight management as Ozempic/Wegovy. Dose escalation protocol over 16-20 weeks.
Dual GIP/GLP-1 receptor agonist. Superior weight loss outcomes in head-to-head trials vs semaglutide (SURMOUNT).
Triple hormone receptor agonist (GLP-1, GIP, glucagon). Next-generation weight management compound in Phase 3 trials.
Long-acting amylin receptor agonist. Studied in combination with semaglutide (CagriSema) for enhanced weight loss.
Modified fragment of human growth hormone (aa 177-191). Stimulates lipolysis without affecting blood sugar or IGF-1.
Multi-pathway weight management blend targeting appetite regulation, lipolysis, and insulin sensitivity.
Body Protection Compound. Pentadecapeptide from human gastric juice, studied for tissue repair, gut healing, and injury recovery.
Thymosin Beta-4 fragment. Systemic tissue repair, wound healing, and inflammation reduction via actin regulation.
Pre-combined BPC-157 + TB-500 in a single vial. Simplified recovery protocol with synergistic mechanisms.
Human cathelicidin antimicrobial peptide. Broad-spectrum immune modulation, anti-biofilm, and wound healing properties.
Mitochondrial-derived peptide. AMPK activator studied for metabolic regulation and exercise mimetic effects.
Copper tripeptide. Naturally occurring in human plasma, studied for skin remodeling, collagen synthesis, and gene expression modulation.
Telomerase activator. Studied for anti-aging effects through telomere length maintenance and pineal gland regulation.
Acetyl octapeptide-3. Topical neuropeptide that modulates the SNARE complex to reduce expression wrinkle depth.
Multi-peptide skin rejuvenation blend. GHK-Cu, AHK-Cu, and SNAP-8 combined for comprehensive anti-aging.
Nicotinamide adenine dinucleotide. Essential coenzyme for sirtuin activation, DNA repair, and mitochondrial function.
Growth hormone releasing hormone analog. Sustained GH elevation. Available with DAC (weekly) or without (Mod GRF 1-29, daily).
Selective GH secretagogue. Cleanest GHRP profile — no significant cortisol, prolactin, or ghrelin elevation.
Pre-combined CJC-1295 (no DAC) + Ipamorelin. The gold-standard GH secretagogue stack in a single vial.
GHRH analog (1-29). Stimulates natural pulsatile GH release from the pituitary. One of the earliest GH peptides studied.
FDA-approved GHRH analog (Egrifta). Specifically studied for visceral fat reduction and body composition improvement.
Combined Ipamorelin + Tesamorelin. Synergistic GH release with targeted visceral fat reduction.
Bremelanotide. FDA-approved melanocortin receptor agonist (Vyleesi) for sexual function via CNS pathways.
GPR54 agonist. Master regulator of the HPG axis, triggering GnRH release for LH/FSH-mediated hormonal support.
ERR agonist exercise mimetic. Preclinical compound studied for muscle fiber conversion and mitochondrial biogenesis.
Synthetic tuftsin analog. Russian-approved anxiolytic with GABA-modulating and BDNF-upregulating properties.
Synthetic ACTH(4-10) analog. Russian-approved neuroprotectant with BDNF/NGF upregulation and cognitive enhancement.
Delta Sleep-Inducing Peptide. Promotes delta-wave sleep stages and modulates the HPA stress axis without sedation.
Amino acid derivative. Shuttles fatty acids into mitochondria for energy production. Injectable and oral forms.
Lipotropic injection blend (MIC + B12). Methionine, inositol, choline, and cyanocobalamin for metabolic support.
Sterile water with 0.9% benzyl alcohol preservative. The standard reconstitution solvent for most lyophilized peptides.
Acidified reconstitution solvent (0.6% acetic acid, pH ~3). Required for peptides with solubility issues at neutral pH.